Dars2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| DARS2 Protein |
|---|
| Protein Name | Aspartyl-tRNA Synthetase 2, Mitochondrial |
| Gene | DARS2 |
| UniProt | Q6PI48 |
| Molecular Weight | 80 kDa |
| Subcellular Localization | Mitochondria matrix |
| Protein Family | Aminoacyl-tRNA synthetase family |
DARS2 (Mitochondrial Aspartyl-tRNA Synthetase 2) is an essential mitochondrial enzyme that catalyzes the attachment of aspartic acid to its cognate tRNA for mitochondrial protein synthesis. It is encoded by nuclear DNA and imported into mitochondria. Mutations in DARS2 cause a distinctive form of leukoencephalopathy with脑stem and spinal cord involvement (LBSL), characterized by white matter abnormalities and selective vulnerability of specific neural tracts[1].
DARS2 has several structural features:
- N-terminal MTS: Mitochondrial targeting sequence for import
- Aminoacyl-tRNA Synthetase Core: Catalytic domain for aminoacylation
- ** Anticodon Binding Domain**: Recognizes the mitochondrial tRNAAsp
- Dimerization Interface: Forms functional homodimers
DARS2 is essential for mitochondrial translation:
- tRNA Charging: Attaches aspartic acid to mitochondrial tRNAAsp
- Mitochondrial Protein Synthesis: Enables translation of 13 mitochondrial-encoded proteins
- Respiratory Chain Assembly: Supports synthesis of OXPHOS complex subunits
- Cellular Energy Metabolism: Maintains ATP production
DARS2 functions in mitochondrial translation:
- Aminoacylation: Catalyzes Asp + tRNAAsp + ATP → Asp-tRNAAsp + AMP + PPi
- Quality Control: Editing domain prevents mischarging
- Complex Formation: Works with other mitochondrial aminoacyl-tRNA synthetases
- Import Coordination: Partners with mitochondrial import machinery
¶ Leukoencephalopathy with Brainstem and Spinal Cord Involvement (LBSL)
Autosomal recessive DARS2 mutations cause LBSL:
Clinical Features:
- Onset in childhood or adolescence
- Progressive gait disturbance
- Lower limb spasticity
- Ataxia
- Variable cognitive impairment
MRI Findings:
- White matter abnormalities (leukoaraiosis)
- Brainstem tract involvement (particularly the pyramidal tracts)
- Spinal cord signal changes
- Periventricular and deep white matter lesions[2]
Pathogenesis:
- Impaired mitochondrial translation
- Reduced respiratory chain function
- Selective vulnerability of long tracts
- Mitochondrial Encephalomyopathy: Rare presentations
- Combined Oxidative Phosphorylation Deficiency
Current treatments under investigation:
- Coenzyme Q10: May support mitochondrial function
- L-Carnitine: Supports fatty acid metabolism
- B-Vitamin Complexes: Metabolic support
- Mitochondrial Biogenesis Agents: Emerging therapies
Key areas of active research:
- Understanding tissue-specific vulnerability in LBSL
- Developing mitochondrial-targeted therapies
- Biomarkers for disease progression
- Genotype-phenotype correlations
The study of Dars2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Scheper GC, et al. (2007). Mitochondrial aspartyl-tRNA synthetase deficiency. Nat Genet. PMID:17293821
- van der Knaap MS, et al. (2012). LBSL: DARS2 mutations. Ann Neurol. PMID:22334516
- Parnetti L, et al. (2019). Mitochondrial translation disorders. J Transl Med. PMID:31189456
- Antonellis A, et al. (2006). Aminoacyl-tRNA synthetases in disease. Annu Rev Genet. PMID:17091978
- Richman TR, et al. (2015). Mitochondrial tRNA synthetases. Biochim Biophys Acta. PMID:25486342
DARS2 shows specific expression patterns:
- Highest expression: Brain (especially white matter), spinal cord
- Moderate expression: Heart, skeletal muscle
- Low expression: Other peripheral tissues
- Mitochondrial matrix: Primary location
- Nuclear encoding: Cytoplasmic translation, mitochondrial import
- Brain cell specificity: High in oligodendrocytes and neurons
- Expressed throughout development
- Critical for mitochondrial function during myelination
DARS2 catalyzes:
- Amino acid activation: AA + ATP → AA-AMP + PPi
- tRNA charging: AA-AMP + tRNA → AA-tRNA + AMP
- Quality control: Proofreading activity ensures accuracy
- Essential for synthesis of mitochondrial-encoded proteins
- Critical for Complex I, III, IV, V subunits
- Maintains oxidative phosphorylation
In LBSL:
- Reduced aminoacylation activity
- Impaired mitochondrial translation
- Energy production deficiency
- White matter degeneration
- Conditional knockout: Brain-specific deletion shows leukoencephalopathy
- Missense mutations: Recapitulate LBSL phenotypes
- Morpholino knockdown: Developmental defects
- Rescue experiments: Functional validation
| Strategy |
Approach |
Status |
| Gene therapy |
AAV-DARS2 delivery |
Preclinical |
| Small molecules |
Translation enhancers |
Discovery |
| Symptomatic |
Energy support |
Supportive care |
| Gene editing |
CRISPR approaches |
Research |
- Lactate levels: Elevated in CSF and blood
- MRI changes: White matter abnormalities
- DARS2 activity: Diagnostic assay potential
- Understanding genotype-phenotype correlations
- Developing gene therapy vectors
- Biomarker development for disease progression
- Understanding tissue-specific vulnerability